1. This phase 2 clinical trial evaluated the use of site-specific treatment, including molecularly targeted therapy based on next-generation sequencing (NGS) results, for patients with cancer of unknown primary site (CUP).
2. The 1-year survival probability was 53.1%, with a durable response to targeted therapy being observed in patients with actionable genetic alterations.
3. Site-specific treatment, including guided targeted therapy based on NGS, is a promising strategy for patients with CUP and warrants further investigation in a randomized clinical trial.
The article “Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site” is an informative and reliable source of information about the potential benefits of using site-specific treatments for CUP. The article provides detailed information about the study design, setting, participants, interventions, outcomes and measures used in the study as well as its findings. The authors also provide clear explanations of their methods and results which makes it easy to understand the implications of their research.
The article does not appear to have any major biases or one-sided reporting as it presents both sides equally and does not make any unsupported claims or omit any points of consideration that could affect the reliability of its findings. Furthermore, all evidence presented is supported by data from the study itself which adds to its credibility. Additionally, there is no promotional content or partiality present in the article which further increases its trustworthiness and reliability.
The only potential issue with this article is that it does not discuss any possible risks associated with using site-specific treatments for CUP such as side effects or other complications that may arise from such treatments. However, this does not significantly detract from the overall trustworthiness and reliability of the article as it still provides valuable insights into the potential benefits of using site-specific treatments for CUP which can be used to inform future research into this area.